{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:58:57Z","timestamp":1788947937339,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Maryilyn Shangraw"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["1UL1TR003098"],"award-info":[{"award-number":["1UL1TR003098"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["TL1TR003100"],"award-info":[{"award-number":["TL1TR003100"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s11095-025-03837-z","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T17:35:36Z","timestamp":1741714536000},"page":"485-502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["In Vitro-In Vivo Correlation Of Amorphous Solid Dispersion Enabled Itraconazole Tablets"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3885-3709","authenticated-orcid":false,"given":"Ana L.","family":"Coutinho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmita","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6904-4851","authenticated-orcid":false,"given":"Samuel","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Gary","family":"Hollenbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen W.","family":"Hoag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-4314","authenticated-orcid":false,"given":"James E.","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"3837_CR1","doi-asserted-by":"crossref","unstructured":"Brouwers J, Brewster ME, Augustijns P. Supersaturating Drug Delivery Systems: The Answer to Solubility-Limited Oral Bioavailability? Journal of Pharmaceutical Sciences. 2009;98:2549\u201372. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916330271. Accessed 1 Nov 2024.","DOI":"10.1002\/jps.21650"},{"key":"3837_CR2","unstructured":"Sporanox (Itraconazole) Oral Solution Package Insert - Janssen - U.S. Food and Drug Administration. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/020657s025lbl.pdf. Accessed 1 Nov 202."},{"key":"3837_CR3","unstructured":"Sporanox (Itraconazole) Capsules Package Insert - Janssen - U.S. Food and Drug Administration. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020083s040s041s044lbl.pdf.. Accessed 1 Nov 202."},{"key":"3837_CR4","doi-asserted-by":"crossref","unstructured":"Peeters J, Neeskens P, Tollenaere JP, Van Remoortere P, Brewster ME. Characterization of the interaction of 2\u2010hydroxypropyl\u2010\u03b2\u2010cyclodextrin with itraconazole at pH 2, 4, and 7. J Pharm Sci. 2002;91:1414\u201322. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916310103. Accessed 1 Nov 2024.","DOI":"10.1002\/jps.10126"},{"key":"3837_CR5","unstructured":"Ashland Product Grades Available: AquaSolvehypromellose acetate succinate (HPMCAS). Ashland; Available from: https:\/\/www.ashland.com\/file_source\/Ashland\/Industries\/Pharmaceutical\/Links\/PC-11608.12_Pharma_Product_Grades.pdf. Accessed 1 Nov 2024."},{"key":"3837_CR6","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1021\/mp8000793","volume":"5","author":"DT Friesen","year":"2008","unstructured":"Friesen DT, Shanker R, Crew M, Smithey DT, Curatolo WJ, Nightingale JAS. Hydroxypropyl Methylcellulose Acetate Succinate-Based Spray-Dried Dispersions: An Overview. Mol Pharmaceutics. 2008;5:1003\u201319. https:\/\/doi.org\/10.1021\/mp8000793.","journal-title":"Mol Pharmaceutics."},{"key":"3837_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1208\/s12249-019-1541-6","volume":"20","author":"M Honick","year":"2019","unstructured":"Honick M, Sarpal K, Alayoubi A, Zidan A, Hoag SW, Hollenbeck RG, et al. Utility of Films to Anticipate Effect of Drug Load and Polymer on Dissolution Performance from Tablets of Amorphous Itraconazole Spray-Dried Dispersions. AAPS PharmSciTech. 2019;20:331. https:\/\/doi.org\/10.1208\/s12249-019-1541-6.","journal-title":"AAPS PharmSciTech."},{"key":"3837_CR8","doi-asserted-by":"crossref","unstructured":"Honick M, Das S, Hoag SW, Muller FX, Alayoubi A, Feng X, et al. The effects of spray drying, HPMCAS grade, and compression speed on the compaction properties of itraconazole-HPMCAS spray dried dispersions. European Journal of Pharmaceutical Sciences. 2020;155:105556. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098720303444. Accessed 1 Nov 2024.","DOI":"10.1016\/j.ejps.2020.105556"},{"key":"3837_CR9","unstructured":"Honick M. Itraconazole-HPMCAS amorphous spray dried dispersions: composition and process factors impacting performance. [Baltimore, MD]: University of Maryland, Baltimore; 2019. Available from: http:\/\/hdl.handle.net\/10713\/11698."},{"key":"3837_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11095-020-02909-6","volume":"37","author":"A Adhikari","year":"2020","unstructured":"Adhikari A, Polli JE. Characterization of Grades of HPMCAS Spray Dried Dispersions of Itraconazole Based on Supersaturation Kinetics and Molecular Interactions Impacting Formulation Performance. Pharm Res. 2020;37:192. https:\/\/doi.org\/10.1007\/s11095-020-02909-6.","journal-title":"Pharm Res."},{"key":"3837_CR11","unstructured":"Zhao G, Wei K, Nguyen D, Lim HL, Rage B, Lu D. FDA Perspective on Dissolution Testing for Development of High-Risk Oral Drug Products Containing Amorphous Solid Dispersions (T1230\u201309\u2013051). American Association of Pharmaceutical Scientist (AAPS) PharmSci 360 Meeting - Salt Lake City - October 22, 2024. Available from: https:\/\/posters.aaps.org\/aaps\/?menu=16&browseby=3&sortby=2&ce_id=2692&trend=19504#!*menu=16*browseby=3*sortby=2*ce_id=2692*trend=19504. Accessed 1 Nov 2024."},{"key":"3837_CR12","unstructured":"Extended-Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro\/In Vivo Correlations - Guidance for Industry. U.S. Food and Drug Administration; 1997. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/extended-release-oral-dosage-forms-development-evaluation-and-application-vitroin-in-vivo-correlations. Accessed 1 Nov 2024."},{"key":"3837_CR13","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1208\/s12248-016-9966-2","volume":"18","author":"S Suarez-Sharp","year":"2016","unstructured":"Suarez-Sharp S, Li M, Duan J, Shah H, Seo P. Regulatory Experience with In Vivo In Vitro Correlations (IVIVC) in New Drug Applications. AAPS J. 2016;18:1379\u201390. https:\/\/doi.org\/10.1208\/s12248-016-9966-2.","journal-title":"AAPS J."},{"key":"3837_CR14","doi-asserted-by":"crossref","unstructured":"Kesisoglou F, Hermans A, Neu C, Yee KL, Palcza J, Miller J. Development of In Vitro\u2013In Vivo Correlation for Amorphous Solid Dispersion Immediate-Release Suvorexant Tablets and Application to Clinically Relevant Dissolution Specifications and In-Process Controls. Journal of Pharmaceutical Sciences. 2015;104:2913\u201322. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916300715.","DOI":"10.1002\/jps.24362"},{"key":"3837_CR15","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1208\/s12249-013-0016-4","volume":"14","author":"TDS Hon\u00f3rio","year":"2013","unstructured":"Hon\u00f3rio TDS, Pinto EC, Rocha HVA, Esteves VSD, Dos Santos TC, Castro HCR, et al. In Vitro\u2013In Vivo Correlation of Efavirenz Tablets Using GastroPlus\u00ae. AAPS PharmSciTech. 2013;14:1244\u201354. https:\/\/doi.org\/10.1208\/s12249-013-0016-4.","journal-title":"AAPS PharmSciTech."},{"key":"3837_CR16","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1007\/s11095-016-1917-1","volume":"33","author":"AY Abuhelwa","year":"2016","unstructured":"Abuhelwa AY, Mudge S, Hayes D, Upton RN, Foster DJR. Population In Vitro-In Vivo Correlation Model Linking Gastrointestinal Transit Time, pH, and Pharmacokinetics: Itraconazole as a Model Drug. Pharm Res. 2016;33:1782\u201394. https:\/\/doi.org\/10.1007\/s11095-016-1917-1.","journal-title":"Pharm Res."},{"key":"3837_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s10928-017-9555-8","volume":"45","author":"AY Abuhelwa","year":"2018","unstructured":"Abuhelwa AY, Mudge S, Upton RN, Foster DJR. Population in vitro\u2013in vivo pharmacokinetic model of first-pass metabolism: itraconazole and hydroxy-itraconazole. J Pharmacokinet Pharmacodyn. 2018;45:181\u201397. https:\/\/doi.org\/10.1007\/s10928-017-9555-8.","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"3837_CR18","doi-asserted-by":"publisher","unstructured":"Veng-Pedersen P, Gobburu JVS, Meyer MC, Straughn AB. Carbamazepine level-A in vivo-in vitro correlation (IVIVC): a scaled convolution based predictive approach. Biopharm Drug Dispo. 2000;21:1\u20136. https:\/\/doi.org\/10.1002\/1099-081X(200001)21:1<1::AID-BDD207>3.0.CO;2-D","DOI":"10.1002\/1099-081X(200001)21:1<1::AID-BDD207>3.0.CO;2-D"},{"key":"3837_CR19","doi-asserted-by":"crossref","unstructured":"Zhang G, Sun M, Jiang S, Wang L, Tan Y, Wang L, et al. Investigating a Modified Apparatus to Discriminate the Dissolution Capacity In Vitro and Establish an IVIVC of Mycophenolate Mofetil Tablets in the Fed State. J Pharm Sci. 2021;110:1240\u20137. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354920306201. Accessed 1 Nov 2024.","DOI":"10.1016\/j.xphs.2020.10.028"},{"key":"3837_CR20","doi-asserted-by":"publisher","unstructured":"Ostrowski M, Wilkowska E, B\u0105czek T. In vivo\u2013in vitro correlation for amoxicillin trihydrate 1000 mg dispersible tablet. Drug Development and Industrial Pharmacy. 2009;25;35:981\u20135. Available from: http:\/\/www.tandfonline.com\/doi\/full\/https:\/\/doi.org\/10.1080\/03639040902737492","DOI":"10.1080\/03639040902737492"},{"key":"3837_CR21","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1208\/s12249-012-9814-3","volume":"13","author":"Y Saibi","year":"2012","unstructured":"Saibi Y, Sato H, Tachiki H. Developing In Vitro\u2013In Vivo Correlation of Risperidone Immediate Release Tablet. AAPS PharmSciTech. 2012;13:890\u20135. https:\/\/doi.org\/10.1208\/s12249-012-9814-3.","journal-title":"AAPS PharmSciTech."},{"key":"3837_CR22","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1021\/acs.molpharmaceut.8b00153","volume":"15","author":"A Ruiz Picazo","year":"2018","unstructured":"Ruiz Picazo A, Martinez-Martinez MT, Col\u00f3n-Useche S, Iriarte R, S\u00e1nchez-Dengra B, Gonz\u00e1lez-\u00c1lvarez M, et al. In Vitro Dissolution as a Tool for Formulation Selection: Telmisartan Two-Step IVIVC. Mol Pharmaceutics. 2018;15:2307\u201315. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00153.","journal-title":"Mol Pharmaceutics."},{"key":"3837_CR23","doi-asserted-by":"crossref","unstructured":"C\u00e1mara-Martinez I, Blechar JA, Ruiz-Picazo A, Garcia-Arieta A, Calandria C, Merino-Sanjuan V, et al. Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen. International Journal of Pharmaceutics. 2022;614:121415. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517321012217. Accessed 1 Nov 2024.","DOI":"10.1016\/j.ijpharm.2021.121415"},{"key":"3837_CR24","doi-asserted-by":"publisher","unstructured":"Kuemmel C, Yang Y, Zhang X, Florian J, Zhu H, Tegenge M, et al. Consideration of a Credibility Assessment Framework in Model\u2010Informed Drug Development: Potential Application to Physiologically\u2010Based Pharmacokinetic Modeling and Simulation. CPT Pharmacom & Syst Pharma. 2020;9:21\u20138. Available from: https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/psp4.12479.","DOI":"10.1002\/psp4.12479."},{"key":"3837_CR25","unstructured":"Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions - Guidance for Industry and Food and Drug Administration Staff. U.S. Food and Drug Administration; 2023. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/assessing-credibility-computational-modeling-and-simulation-medical-device-submissions. Accessed 1 Nov 2024."},{"key":"3837_CR26","doi-asserted-by":"publisher","first-page":"5353","DOI":"10.1021\/acs.molpharmaceut.4c00758","volume":"21","author":"T Heimbach","year":"2024","unstructured":"Heimbach T, MusuambaTshinanu F, Raines K, Borges L, Kijima S, Malamatari M, et al. PBBM Considerations for Base Models, Model Validation, and Application Steps: Workshop Summary Report. Mol Pharmaceutics. 2024;21:5353\u201372. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00758.","journal-title":"Mol Pharmaceutics."},{"key":"3837_CR27","doi-asserted-by":"crossref","unstructured":"Krug SA, Coutinho AL, Polli JE, Kane MA. Validation of a method for itraconazole and major metabolite hydroxyitraconazole for LC-MS\/MS analysis with application in a formulation clinical study. J Pharm Biomed Anal. 2023;234:115505. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523002741. Accessed 1 Nov 2024.","DOI":"10.1016\/j.jpba.2023.115505"},{"key":"3837_CR28","doi-asserted-by":"crossref","unstructured":"Polli JE, Rekhi GS, Augsburger LL, Shah VP. Methods to Compare Dissolution Profiles and a Rationale for Wide Dissolution Specifications for Metoprolol Tartrate tablets. Journal of Pharmaceutical Sciences. 1997;86:690\u2013700. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915503274. Accessed 1 Nov 2024.","DOI":"10.1021\/js960473x"},{"key":"3837_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12248-022-00765-3","volume":"25","author":"JE Polli","year":"2022","unstructured":"Polli JE. A Simple One-Parameter Percent Dissolved Versus Time Dissolution Equation that Accommodates Sink and Non-sink Conditions via Drug Solubility and Dissolution Volume. AAPS J. 2022;25:1. https:\/\/doi.org\/10.1208\/s12248-022-00765-3.","journal-title":"AAPS J."},{"key":"3837_CR30","unstructured":"The Use of Physiologically Based Pharmacokinetic Analyses \u2014 Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls (Guidance for Industry). 2020. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-physiologically-based-pharmacokinetic-analyses-biopharmaceutics-applications-oral-drug-product. Accessed 1 Nov 2024."},{"key":"3837_CR31","doi-asserted-by":"publisher","unstructured":"Heykants J, Van Peer A, Van De Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, et al. The Clinical Pharmacokinetics of Itraconazole: An Overview. Mycoses. 1989;32:67\u201387. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/j.1439-0507.1989.tb02296.x.","DOI":"10.1111\/j.1439-0507.1989.tb02296.x."},{"key":"3837_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1023\/A:1011992518592","volume":"15","author":"JE Polli","year":"1998","unstructured":"Polli JE, Ginski MJ. Human drug absorption kinetics and comparison to Caco-2 monolayer permeabilities. Pharmaceutical Research. 1998;15:47\u201352. https:\/\/doi.org\/10.1023\/A:1011992518592.","journal-title":"Pharmaceutical Research."},{"key":"3837_CR33","doi-asserted-by":"crossref","unstructured":"Adhikari A, Seo PR, Polli JE. Characterization of Dissolution-Permeation System using Hollow Fiber Membrane Module and Utility to Predict in Vivo Drug Permeation Across BCS Classes. Journal of Pharmaceutical Sciences. 2022;111:3075\u201387. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922002957. Accessed 1 Nov 2024.","DOI":"10.1016\/j.xphs.2022.07.002"},{"key":"3837_CR34","unstructured":"Itraconazole Capsule Dissolution Monograph. United States Pharmacopeia; 2019. Available from: https:\/\/www.uspnf.com\/sites\/default\/files\/usp_pdf\/EN\/USPNF\/revisions\/itraconazole-caps-rb-notice-20190531.pdf. Accessed 1 Nov 2024."},{"key":"3837_CR35","doi-asserted-by":"crossref","unstructured":"Herting M, Kleinebudde P. Studies on the reduction of tensile strength of tablets after roll compaction\/dry granulation. European Journal of Pharmaceutics and Biopharmaceutics. 2008;70:372\u20139. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641108001446.","DOI":"10.1016\/j.ejpb.2008.04.003"},{"key":"3837_CR36","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1021\/acs.molpharmaceut.9b00889","volume":"17","author":"AM Stewart","year":"2020","unstructured":"Stewart AM, Grass ME. Practical Approach to Modeling the Impact of Amorphous Drug Nanoparticles on the Oral Absorption of Poorly Soluble Drugs. Mol Pharmaceutics. 2020;17:180\u20139. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00889.","journal-title":"Mol Pharmaceutics."},{"key":"3837_CR37","doi-asserted-by":"crossref","unstructured":"Shah DD, Taylor LS. Chemistry and Ionization of HPMCAS Influences the Dissolution and Solution-Mediated Crystallization of Posaconazole Amorphous Solid Dispersions. Journal of Pharmaceutical Sciences. 2024;S0022354924003514. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924003514. Accessed 1 Nov 2024.","DOI":"10.1016\/j.xphs.2024.08.023"},{"key":"3837_CR38","doi-asserted-by":"crossref","unstructured":"Men S, Polli JE. Microscope-enabled disc dissolution system: Concordance between drug and polymer dissolution from an amorphous solid dispersion disc and visual disc degradation. Journal of Pharmaceutical Sciences. 2024;S0022354924004854. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924004854.","DOI":"10.1016\/j.xphs.2024.10.039"},{"key":"3837_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1208\/s12248-023-00865-8","volume":"25","author":"K Raines","year":"2023","unstructured":"Raines K, Agarwal P, Augustijns P, Alayoubi A, Attia L, Bauer-Brandl A, et al. Drug Dissolution in Oral Drug Absorption: Workshop Report. AAPS J. 2023;25:103. https:\/\/doi.org\/10.1208\/s12248-023-00865-8.","journal-title":"AAPS J."},{"key":"3837_CR40","doi-asserted-by":"crossref","unstructured":"Westergaard H, Dietschy JM. The mechanism whereby bile acid micelles increase the rate of fatty acid and cholesterol uptake into the intestinal mucosal cell. J Clin Invest. 1976;58:97\u2013108. Available from: http:\/\/www.jci.org\/articles\/view\/108465.","DOI":"10.1172\/JCI108465"},{"key":"3837_CR41","doi-asserted-by":"crossref","unstructured":"Sugano K. Possible reduction of effective thickness of intestinal unstirred water layer by particle drifting effect. Int J Pharm. 2010;387:103\u20139. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517309008710. Accessed 1 Nov 2024.","DOI":"10.1016\/j.ijpharm.2009.12.014"},{"key":"3837_CR42","unstructured":"Patel RP, Taylor LS, Polli JE. Impact of drug incorporation into micelle on reduced griseofulvin and meloxicam permeation across a hollow fiber membrane. J Pharm Sci. 2024;S0022354924004520. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924004520."},{"key":"3837_CR43","doi-asserted-by":"crossref","unstructured":"Buchwald P. Direct, differential-equation-based in-vitro\u2013in-vivo correlation (IVIVC) method. J Pharm Pharmacol. 2010;55:495\u2013504. Available from: https:\/\/academic.oup.com\/jpp\/article\/55\/4\/495\/6148198.","DOI":"10.1211\/002235702847"},{"key":"3837_CR44","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/BF00543326","volume":"28","author":"D Brockmeier","year":"1985","unstructured":"Brockmeier D, Dengler HJ, Voegele D. In vitro\u202f? In vivo correlation of dissolution, a time scaling problem? Transformation of in vitro results to the in vivo situation, using theophylline as a practical example. Eur J Clin Pharmacol. 1985;28:291\u2013300. https:\/\/doi.org\/10.1007\/BF00543326.","journal-title":"Eur J Clin Pharmacol."},{"key":"3837_CR45","unstructured":"Bapat P, Schwabe R, Paul S, Tseng Y-C, Bergman C, Taylor LS. Exploring biorelevant conditions and release profiles of ritonavir from HPMCAS-based amorphous solid dispersions. J Pharm Sci. 2024;S0022354924003162. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924003162."},{"key":"3837_CR46","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s11095-008-9569-4","volume":"25","author":"E Jantratid","year":"2008","unstructured":"Jantratid E, Janssen N, Reppas C, Dressman JB. Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update. Pharm Res. 2008;25:1663\u201376. https:\/\/doi.org\/10.1007\/s11095-008-9569-4.","journal-title":"Pharm Res."},{"key":"3837_CR47","doi-asserted-by":"crossref","unstructured":"Kamba M, Seta Y, Kusai A, Nishimura K. Comparison of the mechanical destructive force in the small intestine of dog and human. International Journal of Pharmaceutics. 2002;237:139\u201349. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517302000431.","DOI":"10.1016\/S0378-5173(02)00043-1"},{"key":"3837_CR48","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1208\/s12249-011-9616-z","volume":"12","author":"M Vardakou","year":"2011","unstructured":"Vardakou M, Mercuri A, Barker SA, Craig DQM, Faulks RM, Wickham MSJ. Achieving Antral Grinding Forces in Biorelevant In Vitro Models: Comparing the USP Dissolution Apparatus II and the Dynamic Gastric Model with Human In Vivo Data. AAPS PharmSciTech. 2011;12:620\u20136. https:\/\/doi.org\/10.1208\/s12249-011-9616-z.","journal-title":"AAPS PharmSciTech."},{"key":"3837_CR49","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1023\/A:1016270701021","volume":"12","author":"M Shameem","year":"1995","unstructured":"Shameem M, Katori N, Aoyagi N, Kojima S. Oral Solid Controlled Release Dosage Forms: Roles of GI-Mechanical Destructive Forces and Colonic Release in Drug Absorption Under Fasted and Fed Conditions in Humans. Pharm Res. 1995;12:1049\u201354. https:\/\/doi.org\/10.1023\/A:1016270701021.","journal-title":"Pharm Res."},{"key":"3837_CR50","doi-asserted-by":"publisher","unstructured":"Garbacz G, Klein S, Weitschies W. A biorelevant dissolution stress test device \u2013 background and experiences. Expert Opin Drug Deliv. 2010;7:1251\u201361. Available from: http:\/\/www.tandfonline.com\/doi\/full\/https:\/\/doi.org\/10.1517\/17425247.2010.527943.","DOI":"10.1517\/17425247.2010.527943."},{"key":"3837_CR51","doi-asserted-by":"crossref","unstructured":"Higuchi M, Yoshihashi Y, Tarada K, Sugano K. Minimum rotation speed to prevent coning phenomena in compendium paddle dissolution apparatus. Eur J Pharm Sci. 2014;65:74\u20138. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098714003510. Accessed 1 Nov 2024.","DOI":"10.1016\/j.ejps.2014.09.010"},{"key":"3837_CR52","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1021\/acs.molpharmaceut.5b00154","volume":"12","author":"S Vaithianathan","year":"2015","unstructured":"Vaithianathan S, Raman S, Jiang W, Ting TY, Kane MA, Polli JE. Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets. Mol Pharmaceutics. 2015;12:2436\u201343. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00154.","journal-title":"Mol Pharmaceutics."},{"key":"3837_CR53","doi-asserted-by":"crossref","unstructured":"Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA, et al. Generic lamotrigine versus brand\u2010name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard. Epilepsia. 2015;56:1415\u201324. Available from: https:\/\/onlinelibrary.wiley.com\/10.1111\/epi.13095. Accessed 1 Nov 2024.","DOI":"10.1111\/epi.13095"},{"key":"3837_CR54","doi-asserted-by":"crossref","unstructured":"Wagner JG. Pharmacokinetics for the Pharmaceutical Scientist. 1st ed. CRC Press; 2018. Available from: https:\/\/www.taylorfrancis.com\/books\/9781351425124.","DOI":"10.1201\/9780203743652"},{"key":"3837_CR55","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-012-9280-2","volume":"39","author":"Y Cao","year":"2012","unstructured":"Cao Y, Jusko WJ. Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2012;39:711\u201323. https:\/\/doi.org\/10.1007\/s10928-012-9280-2.","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"3837_CR56","doi-asserted-by":"crossref","unstructured":"Brouwers J, Geboers S, Mols R, Tack J, Augustijns P. Gastrointestinal behavior of itraconazole in humans \u2013 Part 1: Supersaturation from a solid dispersion and a cyclodextrin-based solution. Int J Pharm. 2017;525:211\u20137. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517317303198. Accessed 1 Nov 2024.","DOI":"10.1016\/j.ijpharm.2017.04.029"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03837-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03837-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03837-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T20:00:48Z","timestamp":1743710448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03837-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3837"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03837-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}